Craig Rush

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

Phase 1

Completed

Conditions: Methamphetamine Use Disorder

Interventions: Drug: Methamphetamine
Drug: Methylphenidate
Drug: Placebo oral capsule
Drug: Duloxetine

First Posted Date: 2019-11-26

Last Posted Date: 2023-01-09

Lead Sponsor: Craig Rush

Target Recruit Count: 8

Registration Number: NCT04178993

Locations: 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)

Phase 1

Completed

Conditions: Alcohol Use Disorder

Interventions: Drug: Alcohol
Drug: Duloxetine
Drug: Placebos
Drug: Methylphenidate

First Posted Date: 2018-07-02

Last Posted Date: 2023-07-12

Lead Sponsor: Craig Rush

Target Recruit Count: 19

Registration Number: NCT03575403

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Behavioral Effects of Drugs: Inpatient (35)

Early Phase 1

Completed

Conditions: Cocaine Use Disorder

Interventions: Drug: Cocaine
Drug: Placebo oral capsule
Drug: Methylphenidate

First Posted Date: 2018-05-08

Last Posted Date: 2019-06-25

Lead Sponsor: Craig Rush

Target Recruit Count: 9

Registration Number: NCT03519022

Locations: 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States

Brief Online Interventions for Alcohol Use

Not Applicable

Completed

Conditions: Alcohol Use Disorder

Interventions: Behavioral: Normative Feedback
Behavioral: Working Memory Training
Behavioral: Inhibitory Control Training

First Posted Date: 2018-02-19

Last Posted Date: 2020-01-29

Lead Sponsor: Craig Rush

Target Recruit Count: 444

Registration Number: NCT03438539

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence

Early Phase 1

Completed

Conditions: Cocaine Use Disorders

Interventions: Drug: Bupropion

First Posted Date: 2012-12-03

Last Posted Date: 2018-06-26

Lead Sponsor: Craig Rush

Target Recruit Count: 34

Registration Number: NCT01739192

Locations: 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States

Aripiprazole to Reduce Cocaine Relapse

Phase 1

Completed

Conditions: Cocaine-Related Disorders

Interventions: Drug: Placebos
Drug: Aripiprazole

First Posted Date: 2006-01-13

Last Posted Date: 2017-04-06

Lead Sponsor: Craig Rush

Target Recruit Count: 41

Registration Number: NCT00276874

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy